The online home of Light & Sound International - the entertainment technology monthly. Daily News, Video Hub, Events Listings, Marketplace, Recruitment.
Cerus Endovascular Receives FDA Breakthrough Device Designation for its Contour Neurovascular System™
News provided by
Share this article
Share this article
FREMONT, Calif. and OXFORD, United Kingdom, Feb. 11, 2021 /PRNewswire/ Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Contour Neurovascular System™.
Breakthrough Device Designation is granted to medical devices and device-led combination products that provide the potential for a more effective treatment option for life-threatening or irreversibly debilitating diseases. The designation expedites the traditional development, assessment and review process, and enables medical professionals to get access to new developments quickly.